Novo Nordisk A/S (NYSE:NVO) Reaches New 52-Week Low – Should You Sell?

Novo Nordisk A/S (NYSE:NVO) shares reached a new 52-week low on Tuesday . The stock traded as low as $77.52 and last traded at $77.89, with a volume of 2180674 shares traded. The stock had previously closed at $78.95.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Stifel Nicolaus cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 0.7 %

The firm has a 50-day moving average price of $84.77 and a two-hundred day moving average price of $104.45. The company has a market capitalization of $351.83 billion, a price-to-earnings ratio of 23.80, a PEG ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 47.72%.

Institutional Trading of Novo Nordisk A/S

Several institutional investors and hedge funds have recently bought and sold shares of NVO. Aegis Wealth Management LLC bought a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $479,000. BridgePort Financial Solutions LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth $540,000. Park Square Financial Group LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $29,000. Employees Retirement System of Texas grew its position in shares of Novo Nordisk A/S by 9.9% in the 4th quarter. Employees Retirement System of Texas now owns 72,964 shares of the company’s stock valued at $6,276,000 after acquiring an additional 6,560 shares during the period. Finally, Brucke Financial Inc. acquired a new position in Novo Nordisk A/S during the fourth quarter worth approximately $542,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.